Here, we used a range of tau and aSyn antibodies targeting different epitopes, spanning from the N- to the C-terminal domain, and PTMs to unravel the molecular tau and aSyn signature of AD-LB, AD without LBs (AD) and PD with dementia (PDD) cases and age-matched controls. This evidence concerns the gene MAPT and Parkinson disease.